Research ArticleCancer

Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

See allHide authors and affiliations

Science Translational Medicine  17 Feb 2016:
Vol. 8, Issue 326, pp. 326ra20
DOI: 10.1126/scitranslmed.aad7785

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Killing cancer with a soft touch

Bleomycin is an effective chemotherapy drug that is used against multiple different types of cancer. Unfortunately, it often causes lung fibrosis or stiffening of the lungs, the severity of which correlates with the extent of exposure to the drug. To overcome this problem, Burgy et al. produced deglycobleomycin, a modified version of the drug that was just as effective against several different models of cancer but did not cause any detectable fibrosis in mouse lungs. If these findings are confirmed in clinical testing, deglycobleomycin could be a valuable addition to the therapeutic regimens for a variety of human cancers.

View Full Text

Stay Connected to Science Translational Medicine